CI
NRXP icon

Cowen Inc’s NRX Pharmaceuticals NRXP Stock Holding History

Cowen Inc’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,613
Closed -$167K – 522
2019
Q1 		$167K Sell
1,613
-1,550
-49% -$159K 0.02% 207
2018
Q4 		$323K Buy
+3,163
New +$320K 0.04% 198

Other funds holding NRXP

MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

Cowen Inc's NRXP Position: Q2 2019 in Review

Cowen Inc sold out of NRX Pharmaceuticals (NRXP) in Q2 2019, closing a stake of 1,613 shares — an estimated $167K sold.

Cowen Inc first reported a position in NRXP in Q4 2018 and held it in 2 quarters. The position peaked at $323K in Q4 2018. 17 funds tracked by Wall St. Rank hold NRXP as of Q2 2019.

  • Cowen Inc reported no remaining NRX Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Cowen Inc sold 1,613 NRX Pharmaceuticals shares in Q2 2019, an estimated $167K.
  • Cowen Inc first reported a position in NRX Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Cowen Inc's NRX Pharmaceuticals position peaked at $323K in Q4 2018.
  • 17 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2019.

Based on Cowen Inc's 13F filing for Q2 2019, filed 14 Aug 2019.